Background/Aims: Imbalance of oxidative/antioxidative enzymes in cells is associated with carcinogenesis and cancer cell chemoresistance. The aim of this study was to examine the clinical significance of potentially functional single nucleotides polymorphisms (SNPs) in antioxidative enzymes, GPxs and CAT, in stages II and III gastric cancer patients. Methods: A total of 591 gastric cancer patients who had radical gastrectomy were recruited. 207 patients received platinum and fluorouracil-based (PF-based) adjuvant chemotherapy and 384 patients were untreated. GPx1 rs1050450, GPx2 rs4902346, GPx3 rs736775, rs3828599 and CAT rs769218 were genotyped in the DNA samples extracted from paraffin-embedded tumor tissue. Results: CAT rs769218 was significantly correlated with the overall survival (OS) in the dominant model (P = 0.014). Multivariate analysis revealed that CAT rs769218 GA/AA (HR, 0.715; 95%CI, 0.562-0.910, P = 0.006) was an independent prognostic marker indicating improved survival. After adjustments, GPx3 rs736775 TC/CC was significantly associated with improved OS (HR, 0.621; 
Introduction
Gastric cancer (GC) is the fourth most commonly diagnosed cancer worldwide and the second leading cause of cancer deaths in China [1] [2] [3] . Surgical resection is still the only curative treatment option for gastric cancer patients. Despite the implement of perioperative chemotherapy and chemoradiation therapy, the 5-year survival rate was only improved by 5-15% [4] [5] [6] [7] ._ENREF_1_ENREF_1 Currently, platin and fluorouracilbased (PF-based) adjuvant chemotherapy is recommended by the main clinical practice guidelines as the standard of care for post-operative gastric cancer patients with stage II and III disease. Conventional clinicopathological parameters or comprehensive molecular classification using The Cancer Genome Atlas (TCGA) datasets only provide prognostic and tumor biological information [8] , but not able to predict patients who would be benefit from adjuvant chemotherapy. Therefore, it is necessary to identify biomarkers that can be used to guide personalized therapy, exempting those patients from unnecessary potential exposure to toxicity and the financial burden of chemotherapy treatments.
The intrinsic regulation of reactive oxygen species (ROS) in cancer cells is one of the various molecular mechanisms involved in multidrug resistance and maintenance of cancer stemness [9, 10] , which is considered as major causes of poor survival after multimodalities anti-cancer treatment. Increasing level of ROS has been observed in many cancer types and associated with activation of cancer initiation and progression related signaling, such as mitogen-activated protein (MAP) kinase/Erk [11] , phosphoinositide-3-kinase (PI3K)/Akt [12] as well as the IκB kinase (IKK)/nuclear factor κ-B (NF-κB) pathways [13] . Chemotherapeutics such as platinum, taxane and fluorouracil may induce cancer cells death through inducing oxidative stress to highly toxic level. In the process of protecting cancer cells from oxidative damage, superoxide dismutases (SODs) convert superoxide radical into hydrogen peroxide, which is further detoxified into water by glutathione peroxidases (GPxs) and catalase (CAT). Cancer stem cells could survive through chemo drug-induced cells death and initiate recurrence by utilizing redox-regulatory mechanisms [14] . In response to chemotherapeutics and cytotoxic by-products, redox signaling pathways are frequently activated in cancer cells to acquire drug resistance [15, 16] . In pancreatic cancer stem cells, chemoresistance to 5-fluorouracil and gemcitabine was related with suppressed ROS levels [17] . Active GPx1 was found in glioma stem cell lines, which mediated their resistant to oxidative stress induced cell death [18] .
Genetic variations of antioxidant genes may alter their activity or function, contributing to the imbalance of ROS production and scavenging. GPx1 rs1050450 polymorphism causes a proline-leucine substitution at codon 198, which correlated with lipid peroxidation, GPx1 activity and breast cancer risk [19] . C-262T polymorphisms at CAT affected its expression in cells and serum level [20, 21] . Previously, we reported SOD2 rs4880, which may regulate SOD2 catalyzation activity, could predict gastric patients' survival after receiving adjuvant chemotherapy [22] . However, the clinical significance of the genetic variations of the antioxidative enzymes regulating hydrogen peroxide scavenging has not been examined. Herein, we investigated the association of potentially functional single nucleotides polymorphisms (SNPs) in CAT, GPx1, GPx2 and GPx3 with adjuvant chemotherapy outcome in gastric cancer patients. Table 1 . Surgical specimens were processed immediately after the operation by fixing in buffered paraformaldehyde before embedding in paraffin. The samples used for genotyping were reviewed and classified by 2 independent pathologists. The study protocol was approved by the Institutional Review Board of Nanjing Medical University (Nanjing, China). All patients have given written informed consents on the use of clinical specimens for medical research.
Treatment plan
The adjuvant chemotherapy consisted of at least 4 cycles of PF-based regimens, including combinations of cisplatin and 5-fluorouracil, oxaliplatin and 5-fluorouracil. Chemotherapy was given only if the patient had neutrophil count of ≥ 1.5×10 9 /L, platelet count of ≥ 100×10 9 /L, hemoglobin level of ≥ 8 g/dl and no sign of organ toxicity. Antiemetics and mannitol diuresis were given according to institutional protocols.
SNP selection
All common (minor allele frequency, MAF > 0.05 in the Han Chinese) polymorphisms in hydrogen peroxide scavenging related genes, GPx and CAT, with potentially functional significance, that is, located at 5'-flanking regions (5'-FRs), 5'-untranslated regions (5'-UTRs), coding regions, or 3'-UTRs according to NCBI dbSNPs were identified. SNPs that were demonstrated to be of biological significance or associated with gene expression and/or cancer risk/survival according to the literature review were also included. If SNPs are in high linkage disequilibrium (LD) (r 2 > 0.8), only one SNP were genotyped. As a result, GPx1 rs1050450, GPx2 rs4902346, GPx3 rs736775, rs3828599 and CAT rs769218 were selected for genotyping and analysis (Table 2) .
Genotyping
Genomic DNA was extracted from tumor specimens by proteinase K digestion, isopropanol extraction, and ethanol precipitation [24] . The SNPs were examined by multiplex TaqMan technology using ABI fluorescence-based allelic discrimination method (Applied Biosystems, Foster City, CA) as described previously [25] . The SNPs were analyzed using ABI 7900, and the genotypes were determined by using GeneMapper 4.0 software (Applied Biosystems). Genotyping was validated in randomly selected 10% of samples by Sanger sequencing, and the results were 100% concordant.
Statistical analysis
The SPSS Statistical Package for Windows (version 16; SPSS Inc. Chicago, IL) was used for data analysis. All statistical tests were two-sided, and an association was considered statistically significant with a P value of < 0.05. Kaplan-Meier survival curves and the log-rank test were used for survival analysis. Chi-squared test was used to assess differences in the frequencies of characteristics between patient sub-groups. Cox regression was used in the univariate survival analysis to determine the association of individual clinicopathologic variables with overall survival. All variables with P < 0.05 in addition to age, sex and treatment arms were subsequently subjected to the multivariate Cox regression analysis in the corresponding cohort to determine the hazards ratios (HRs) and the independence of effects. Because of the exploratory nature of the study, all P values were not adjusted for multiple comparisons [26] .
Results

Patient Characteristics and Associations with the 5 SNPs
Among the 591 patients, GPx1 rs1050450, GPx2 rs4902346, GPx3 rs736775, rs3828599 and CAT rs769218 were successfully determined in more than 96% of the samples ( Table 2) . The associations between their genotypes and patient characteristics were examined. CAT rs769218 GA/GG were correlated with tumor at antrum (P = 0.003). GPX3 rs736775 TC/CC were associated with intestinal type of gastric adenocarcinoma (P = 0.036). In this population, 207 patients received PF-based adjuvant chemotherapy and 384 patients were untreated. As shown in the Table 1 , patients over 60-year old tended to not have adjuvant chemotherapy (P = 0.002). The median age of patients treated with PF-based adjuvant chemotherapy was 59 years and that of untreated patients was 63 years. None of the rest clinicopathological parameters were found significantly different between the two cohorts. Excepted for GPx1 rs1050450 (P = 0.029), the allele distributions of the rest SNPs were consistent between different treatment groups.
GPx3 rs736775 and CAT rs769218 as Prognostic Markers
Univariate Cox regression was used to examine the associations between the 5 SNPs and OS in the total patients by using different genetic models ( Table 2) . P-values of Hardy-Weinberg equilibrium (HWE) were all greater than 0.05. None of GPxs related SNPs were found to have significant association with the OS. CAT rs769218 was significantly correlated with the OS in the dominant model (P = 0.014). Comparing to the patients carrying rs769218 GG, those with GA/AA had a longer mean overall survival time (MST) of 69 months (Log-rank = 6.211, P = 0.013). As for the conventional clinicopathological variables, lymph node metastasis (P = 0.011) and tumor stage (P < 0.001) were significantly correlated with postoperative OS in the total patients. Multivariate analysis revealed that CAT rs769218 GA/AA (HR, 0.715; 95%CI, 0.562-0.910, P = 0.006) was an independent prognostic marker indicating improved survival beside advanced tumor stage (HR, 1.868; 95%CI, 1.145-3.047; P = 0.012, Table 3 ).
The overall survival time did not show significant difference between patients treated with PF-based adjuvant chemotherapy and those untreated. Poor tumor Fig. 1A ).
No such association was observed for the patients without adjuvant chemotherapy (Fig. 1B) . The OS was not statistically different in treated patients with CAT rs769218 GG or GA/AA genotypes ( Fig. 2A) . However, in the untreated arm, CAT rs769218 GG was associated with shorter MST of 55 months than those carrying GA/AA (MST, 69 
GPx3 rs736775 Polymorphisms as a Predictive Marker
When the patients were divided by the genetic models, none of GPx1 rs1050450, GPx2 rs4902346, GPX3 rs3828599 or CAT rs769218 genotypes associated with survival benefit from adjuvant chemotherapy (all P >0.05). Initial analysis showed the treatment benefit was present in patients with GPx3 rs736775 TC/CC but not in those with TT genotype (Fig.  3A and 3B) . The MST was 69 months for the patients treated with PFbased adjuvant chemotherapy, which is significantly longer than the MST (60 months) of untreated patients (Log-rank = 3.953, P = 0.047). For the patients carrying GPx3 rs736775 TC/CC, lymph node metastasis (P = 0.008) and tumor stage (P = 0.001) were significantly associated with OS in univariate analysis. When adjusted by age, sex and these cofounders, adjuvant chemotherapy showed a trend towards lower risk of death than untreated patients with GPx3 rs736775 TC/CC (HR, 0.698; 95% CI, 0.471-1.034; P = 0.073). We further performed stratification analysis. No treatment benefit was observed in patients with GPx3 rs736775 TC/CC of stage II (HR, 0. 724; 95% CI, 0.310-1.694; P = 0.457) or stage III disease (HR, 0.708; 95% CI, 0.453-1.108; P = 0.131). PF-based chemotherapy significantly decreased risk of death for patients carrying GPx3 rs736775 TC/CC and age ≤ 60 years (HR, 0.542; 95% CI, 0.303-0.970; P = 0.039; Fig. 4A ) or with diffused type adenocarcinoma (HR, 
0.506; 95% CI, 0.308 to 0.831; P = 0.007; Fig. 4C ) compared to surgery alone. As for patients carrying GPx3 rs736775 TT, no protective effect from adjuvant chemotherapy was observed in those at younger age or with the diffused type of tumor ( Fig.  4B and 4D ).
Discussion
Adjuvant PF-based therapy in patients with locally advanced (stage II or III) gastric adenocarcinoma is well accepted worldwide. Both CLASSIC (Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer) and ACTS-GC (Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer) studies demonstrated a significant increase of 5-year overall survival rate by only 10-15% given the adjuvant chemotherapy [27, 28] . The modest clinical benefit of PF-based adjuvant chemotherapy in gastric cancer patients underlines the need for prognostic and predictive markers to optimize the surveillance and treatment strategy.
In the present study, the clinical associations of 5 SNPs of 4 redox related genes, CAT and GPx1-3, were explored in stage II-III postoperative gastric cancer patients. CAT rs769218 was a significant prognostic marker independent of age, sex, lymph node involvement, tumor differentiation, Lauren classification and tumor stage in postoperative patients. Further stratification analysis revealed the protective effect of rs769218 GA/GG on overall survival was observed in patients without adjuvant chemotherapy. On the other hand, GPx3 rs736775 TC/CC was associated with improved overall survival in patients received PF-based adjuvant chemotherapy. Both of their prognostic effects maintained in multivariate models.
Regarding as predictive markers, none of the 5 SNPs was demonstrated of significant association with treatment benefit in multivariate models. Although PF-based adjuvant chemotherapy showed a trend towards lower risk of death for patients with GPx3 rs736775 TC/CC (adjusted HR, 0.68; P = 0.053), our data do not support GPx3 rs736775 TC/CC as a sole biomarker to recommend PF-based adjuvant treatment for patients with either stage II or III disease. For patients with GPx3 rs736775 TC /CC, age (≤ 60 years) and tumor differentiation (diffused type) should be taken into consideration to recommend this regimen.
Patients after radical surgery and adjuvant therapy, cancer progression often occur and be subject to local recurrence and distant metastasis, which are partially related with chemoresistance and cancer stem cell persistence. Fluorouracil and platin are commonly used in adjuvant chemotherapy, which may be able to eliminate micrometastasis lesion through increasing intracellular ROS level and subsequently inducing cell death [17, 29] . Increased ROS have shown both pros and cons in cancer initiation and progression [30] . High level of ROS was found in tumor cells than adjacent nontumor counterparts, which cause damage to nucleic acids and lead to mutation, genomic instability and carcinogenesis. However, reducing ROS level through antioxidants accelerated tumor development and metastatic potential in lung [31] , melanoma [32, 33] and breast cancer cells [34] . Activation Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of redox signaling or its related elements have been found to associate with maintaining low intracellular ROS level and contribute to cancer stem cell survive and chemoresistance [35, 36] . CAT and GPxs are major cellular antioxidants reducing oxygen free radicals like H 2 O 2 . CAT expression was reported to increase [37] or decrease [38] in gastric carcinoma compared to non-tumor tissue. Under-expression of CAT in cancer cells related with chemoresistance to doxorubicin [39] . Retaining CAT activity showed enhancing cisplatin toxicity in breast cancer mouse models [40] . Genetic variation in CAT have been found to associate with impaired CAT activity and certain diseases [41] . Two common CAT SNPs, rs1001179 and rs794316, were found to be associated with prostate cancer risk and survival [42, 43] . So far, there is no riskrelated CAT polymorphisms identified in gastric cancer [44, 45] . Rs769218, an intronic SNP in CAT, was found associated with breast overall survival in patients who did not received radiotherapy [46] . In our study, CAT rs769218 GG was associated with poor overall survival compared to GA/AA genotypes in patients without PF-based adjuvant chemotherapy. These results suggest CAT rs769218 may have potential effect modified by treatment and further functional studies are needed.
GPx3 was found frequently down-regulated in cancer tissues including breast, lung and gastric cancer [47] , which may due to its promoter hypermethylation [48] [49] [50] . Silencing or decreased activity of GPX3 is correlated with increased ROS level and contributes to cancer initiation [51] and metastasis [52, 53] . Reduced expression of GPx3 could enhance platin sensitivity in colorectal cancer [54] , and increased expression was related with low intracellular ROS level and maintaining cancer stem cell phenotype in leukemia stem cells [36] . Two intronic polymorphisms of GPx3, rs3805435 and rs3828599, were shown to influence gene expression and correlate with gastric cancer risk [55] . GPx3 rs736775 C allele was found indicating better survival in colorectal cancer [56] . In our study, the protective effect of GPx3 rs736775 C allele was demonstrated in patients treated with PF-based adjuvant therapy. Whether this polymorphism has an effect on its expression needs further investigation.
Although our study showed the presence of CAT rs769218 GA/AA or GPx3 rs736775 TC/ CC were important prognostic and/or predictive markers for certain gastric cancer patients, there are several cautions should be noted. Patients in this analysis were from a Chinese retrospective cohort and allele's distribution could be different worldwide. The clinical significance of CAT rs769218 and GPx3 rs736775 in gastric cancer should be verified in other populations and patients from randomized clinical trials. Second, there is no consensus on adjuvant chemo regimen for gastric cancer. Taxane, platin and fluorouracil-based drugs such as capecitabine and S-1, were often used in different combinations. Our data only showed patients with GPx3 rs736775 TC/CC could be benefit from PF-based chemotherapy, thus, it may not be appropriate for guiding adjuvant chemotherapy if other regimens were employed. Third, the biological functions of these genetic variations were not investigated or reported in the literature. Future studies that examining those variants related gene transcription and function would be useful for improve adjuvant chemotherapy efficacy.
In conclusion, CAT rs769218 GA/AA and GPx3 rs736775 TC/CC could serve as prognostic markers for postoperative gastric cancer patients. Moreover, GPx3 rs736775 genetic models showed specific influences on PF-based adjuvant chemotherapy outcome in some subtypes of gastric cancer. These results suggested that combined with pathological parameters and GPx3 rs736775 genotypes could help clinical decision-making. Future prospective clinical trials to validate these findings and design for effective regimens for personalized therapy are needed.
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